Direct detection of early-stage cancers using circulating tumor DNA
Top Cited Papers
- 16 August 2017
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (403)
- https://doi.org/10.1126/scitranslmed.aan2415
Abstract
Early detection and intervention are likely to be the most effective means for reducing morbidity and mortality of human cancer. However, development of methods for noninvasive detection of early-stage tumors has remained a challenge. We have developed an approach called targeted error correction sequencing (TEC-Seq) that allows ultrasensitive direct evaluation of sequence changes in circulating cell-free DNA using massively parallel sequencing. We have used this approach to examine 58 cancer-related genes encompassing 81 kb. Analysis of plasma from 44 healthy individuals identified genomic changes related to clonal hematopoiesis in 16% of asymptomatic individuals but no alterations in driver genes related to solid cancers. Evaluation of 200 patients with colorectal, breast, lung, or ovarian cancer detected somatic mutations in the plasma of 71, 59, 59, and 68%, respectively, of patients with stage I or II disease. Analyses of mutations in the circulation revealed high concordance with alterations in the tumors of these patients. In patients with resectable colorectal cancers, higher amounts of preoperative circulating tumor DNA were associated with disease recurrence and decreased overall survival. These analyses provide a broadly applicable approach for noninvasive detection of early-stage tumors that may be useful for screening and management of patients with cancer.Funding Information
- NIH Office of the Director (award306623, CA121113)
- NIH Office of the Director (award306624, CA006973)
- NIH Office of the Director (award306625, CA180950)
- Commonwealth Foundation (award306628)
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (award306626)
- Stand Up To Cancer (award306627, SU2C-AACR-DT1415)
- Novo Nordisk (award306631, NNF14OC0012747)
- Danish Council for Independent Research (award306629, 11-105240)
- The Danish Council for Strategic Research (award306630, 1309-00006B)
- The Danish Cancer Society (award306632, R133-A8520)
- The Danish Cancer Society (award306633, R40-A1965-11-S2)
This publication has 39 references indexed in Scilit:
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerThe New England Journal of Medicine, 2013
- Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome SequencingScience Translational Medicine, 2012
- High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy NumberAnalytical Chemistry, 2011
- Detection and quantification of rare mutations with massively parallel sequencingProceedings of the National Academy of Sciences of the United States of America, 2011
- A scalable, fully automated process for construction of sequence-ready human exome targeted capture librariesGenome Biology, 2011
- The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice through activation of Wnt and ERK1/2 MAPK pathwaysOncogene, 2010
- COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancerNucleic Acids Research, 2009
- The Consensus Coding Sequences of Human Breast and Colorectal CancersScience, 2006
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982
- Preoperative Carcinoembryonic Antigen Level as a Prognostic Indicator in Colorectal CancerThe New England Journal of Medicine, 1978